This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freedman, K. B.
Right arrow Articles by Lane, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freedman, K. B.
Right arrow Articles by Lane, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
The Journal of Bone and Joint Surgery 81:1652-3 (1999)
© 1999 The Journal of Bone and Joint Surgery, Inc.

Correspondence

Correspondence

Kevin B. Freedman, M.D., Laura L. Tosi, M.D. and Joseph M. Lane, M.D.

TO THE EDITOR:

I read "Editorial. Osteoporosis Prevention and the Orthopaedic Surgeon: When Fracture Care Is Not Enough" (80-A: 1567–1569, Nov. 1998), by Tosi and Lane, with great interest. These authors are to be commended for their excellent review of the role of the orthopaedic surgeon in the prevention and treatment of osteoporosis. In their review, the authors cited the recently approved "Standardization of Medicare Coverage of Bone Mass Measurement," which defines five diagnostic categories that meet approval for the use of bone-density technologies: (1) estrogen-deficient women who are at clinical risk for osteoporosis, (2) patients who have vertebral abnormalities, (3) patients who are receiving long-term glucocorticoid therapy, (4) patients who have primary hyperparathyroidism, and (5) patients who are being monitored to assess the response to, or the efficacy of, an approved drug for osteoporosis. I am writing to suggest that a sixth category be established: postmenopausal women who have . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?